| 1 |
Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study.
|
|
|
|
In: HIV medicine, vol. 23, no. 4, pp. 441-447 (2022)
|
|
BASE
|
|
Show details
|
|
|
| 2 |
A Therapeutic Relational Agent for Reducing Problematic Substance Use (Woebot): Development and Usability Study.
|
|
|
|
In: Journal of medical Internet research, vol 23, iss 3 (2021)
|
|
BASE
|
|
Show details
|
|
|
| 3 |
New Directions in Treatments Targeting Stroke Recovery.
|
|
|
|
In: Stroke, vol 49, iss 12 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 4 |
Cognitive Working Memory Training (CWMT) in adolescents suffering from Attention-Deficit/Hyperactivity Disorder (ADHD): A controlled trial taking into account concomitant medication effects.
|
|
|
|
In: Psychiatry research, vol. 269, pp. 79-85 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 5 |
Refractory depression: mechanisms and evaluation of radically open dialectical behaviour therapy (RO-DBT) [REFRAMED]: protocol for randomised trial.
|
|
Lynch, TR; Whalley, B; Hempel, RJ; Byford, S; Clarke, P; Clarke, S; Kingdon, D; O'Mahen, H; Russell, IT; Shearer, J; Stanton, M; Swales, M; Watkins, A; Remington, B. - : BMJ Publishing Group, 2015
|
|
Abstract:
This is the final version of the article. Available from the publisher via the DOI in this record. ; INTRODUCTION: Only 30-40% of depressed patients treated with medication achieve full remission. Studies that change medication or augment it by psychotherapy achieve only limited benefits, in part because current treatments are not designed for chronic and complex patients. Previous trials have excluded high-risk patients and those with comorbid personality disorder. Radically Open Dialectical Behaviour Therapy (RO-DBT) is a novel, transdiagnostic treatment for disorders of emotional over-control. The REFRAMED trial aims to evaluate the effectiveness and cost-effectiveness of RO-DBT for patients with treatment-resistant depression. METHODS AND ANALYSIS: REFRAMED is a multicentre randomised controlled trial, comparing 7 months of individual and group RO-DBT treatment with treatment as usual (TAU). Our primary outcome measure is depressive symptoms 12 months after randomisation. We shall estimate the cost-effectiveness of RO-DBT by cost per quality-adjusted life year. Causal analyses will explore the mechanisms by which RO-DBT is effective. ETHICS AND DISSEMINATION: The National Research Ethics Service (NRES) Committee South Central - Southampton A first granted ethical approval on 20 June 2011, reference number 11/SC/0146. TRIAL REGISTRATION NUMBER: ISRCTN85784627. ; This project is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership, grant number EME 09/ 150/12. REFRAMED is sponsored by the University of Southampton. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NHS, NIHR or the Department of Health.
|
|
Keyword:
Behavior Therapy; Cost-Benefit Analysis; Depression; Drug Resistance; Humans; Quality-Adjusted Life Years; Radically Open Dialectical Behaviour Therapy; Refractory Depression; Research Design; Retreatment; Study Protocol
|
|
URL: http://hdl.handle.net/10871/26507
https://doi.org/10.1136/bmjopen-2015-008857
|
|
BASE
|
|
Hide details
|
|
|
| 6 |
Painful oral aphthous-like lesions in patient with kidney cancer after target therapy and bisphosphonate administration: a case report of adverse drug reaction.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 7 |
Refractory depression: mechanisms and evaluation of radically open dialectical behaviour therapy (RO-DBT) [REFRAMED]: protocol for randomised trial.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 8 |
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial
|
|
|
|
In: PMC (2013)
|
|
BASE
|
|
Show details
|
|
|
| 9 |
Innovative solutions to novel drug development in mental health.
|
|
|
|
In: Symplectic Elements at Oxford ; Europe PubMed Central ; PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) ; Web of Science (Lite) (http://apps.webofknowledge.com/summary.do) ; Scopus (http://www.scopus.com/home.url) ; CrossRef (2013)
|
|
BASE
|
|
Show details
|
|
|
| 10 |
Innovative solutions to novel drug development in mental health.
|
|
|
|
In: Neurosci Biobehav Rev , 37 (10 Pt 1) pp. 2438-2444. (2013) (2013)
|
|
BASE
|
|
Show details
|
|
|
| 11 |
An evaluation of the parents under pressure programme: a study protocol for an RCT into its clinical and cost effectiveness
|
|
|
|
BASE
|
|
Show details
|
|
|
| 12 |
Research Article ASSESSMENT OF COLLEGE STUDENT’S AWARENESS ABOUT TUBERCULOSIS IN AHMEDNAGAR
|
|
|
|
In: http://www.ijrdpl.com/docs/5th/6 Res.pdf (2012)
|
|
BASE
|
|
Show details
|
|
|
| 13 |
Association between ambulatory 24-hour blood pressure levels and brain volume reduction: a cross-sectional elderly population-based study
|
|
|
|
In: ISSN: 1524-4563 ; Hypertension (Dallas, Tex. : 1979) ; https://hal.univ-angers.fr/hal-03355591 ; Hypertension (Dallas, Tex. : 1979), 2012, 60 (5), pp.1324-31. ⟨10.1161/hypertensionaha.112.193409⟩ (2012)
|
|
BASE
|
|
Show details
|
|
|
| 14 |
Basal insulin and cardiovascular and other outcomes in dysglycemia.
|
|
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 319-328 (2012)
|
|
BASE
|
|
Show details
|
|
|
| 15 |
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
|
|
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 309-318 (2012)
|
|
BASE
|
|
Show details
|
|
|
| 16 |
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
|
|
|
|
In: New England Journal of Medicine, vol. 367, no. 23, pp. 2204-2213 (2012)
|
|
BASE
|
|
Show details
|
|
|
| 17 |
Crossover trial of subacute computerized aphasia therapy for anomia with the addition of either levodopa or placebo
|
|
|
|
In: ISSN: 1545-9683 ; Neurorehabilitation and Neural Repair, Vol. 25, No 1 (2011) pp. 43-47 (2011)
|
|
BASE
|
|
Show details
|
|
|
| 18 |
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
|
|
|
|
In: Journal of Bone and Mineral Research, vol. 26, no. 5, pp. 984-992 (2011)
|
|
BASE
|
|
Show details
|
|
|
| 20 |
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
|
|
|
|
In: Osteoporosis International, vol. 21, no. 7, pp. 1277-1285 (2010)
|
|
BASE
|
|
Show details
|
|
|
|
|
